FDA Approves Pimicotinib for Tenosynovial Giant Cell Tumor

The kinase inhibitor is approved for adults with symptomatic tumors where surgery may cause severe functional limitation or morbidity.

Updated on Nov. 10, 2026 in Cancer

FDA Approves Pimicotinib for Tenosynovial Giant Cell Tumor

The U.S. Food and Drug Administration approved pimicotinib, sold as Pimjetmi, on November 10, 2026, for adults with symptomatic tenosynovial giant cell tumor. The approval covers patients for whom surgical removal may worsen functional limitation or cause severe morbidity.

Why it matters

The approval adds a treatment option for a rare tumor where surgery carries risks of significant functional loss. The FDA review was conducted under Project Orbis alongside regulators in Australia, Canada, Israel, Switzerland and the United Kingdom.

The approval rests on the MANEUVER Phase 3 trial, which randomized patients 2:1 to pimicotinib 50 mg daily or placebo, with lesions of at least 2 cm required for eligibility. Efficacy figures are not detailed in the available extraction, and the report does not address the drug's effect relative to placebo.

The players

U.S. Food and Drug Administration (FDA)

The U.S. federal agency responsible for approving drugs and medical products for sale in the United States, including new kinase inhibitors for rare tumors.

Project Orbis

An FDA-led international oncology initiative that allows concurrent review of cancer drug applications with partner regulators.

The details

Pimicotinib is a kinase inhibitor taken orally once daily at 50 mg, with or without food. The most common adverse reactions above 20% were pruritus, rash, face and periorbital edema, fatigue, nausea, headache and peripheral edema. Prescribing information includes warnings for hepatotoxicity, embryo-fetal toxicity, and increased serum creatinine without renal function change. The drug had previously received fast track and breakthrough therapy designation.

Timeline

  1. November 10, 2026: FDA approves pimicotinib (Pimjetmi) for symptomatic tenosynovial giant cell tumor.

Big Picture

The review ran under Project Orbis, the FDA-led initiative that lets regulators in Australia, Canada, Israel, Switzerland and the United Kingdom assess oncology applications in parallel. Pimicotinib's approval extends that coordinated model to a treatment for tenosynovial giant cell tumor, a rare condition with few approved systemic options.

Patients with symptomatic tenosynovial giant cell tumor for whom surgery may cause serious functional loss now have a prescription option. The label warns about liver injury, embryo-fetal harm and rising creatinine, so monitoring with a treating clinician will matter.

The takeaway

A new oral option may change the surgical decision for some patients with this tumor, but the label's liver, pregnancy and kidney-marker warnings call for close clinical follow-up.

Further reading

For broader context on drug approvals for tumors like this, explore our Cancer coverage.